CAMBRIDGE, Mass., August 7, 2020 – Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences.

Presentation Details:

Event: BTIG Virtual Biotechnology Conference
Date: Monday, August 10, 2020
Time: 9:00 AM ET
Details: Fireside chat

Event: Canaccord Genuity 40th Annual Growth Conference
Date: Thursday, August 13, 2020
Time: 1:30 PM ET
Details: Corporate presentation

Event: Oppenheimer Private Life Sciences Company Call Series
Date: Wednesday, August 19, 2020
Time: 9:30 AM ET
Details: Corporate presentation

About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor Contact
Glenn Reicin
Sigilon Therapeutics, Chief Financial Officer
glenn.reicin@sigilon.dev.cc
646-696-4344

Media Contact
Amy Bonanno
Solebury Trout
abonanno@troutgroup.com
914-450-0349